Medistem Panama Founder Granted US Patent On Cancer Treatment Based On Patient's Own Cells

Main Category: Cancer / Oncology
Article Date: 07 Jul 2010 - 11:00 PDT

email to a friend   printer friendly   opinions  

Medistem Inc. (PINKSHEETS: MEDS). Medistem Panama, licensee of Medistem Inc., announced today issuance of US patent # 7,749,495 covering a new method for treating cancer that does not require use of chemotherapy or radiation. The procedure, which involves taking out patient cells, manipulating them, and re-introducing them into the body, has demonstrated positive results in patients with metastatic renal cell carcinoma, neuroblastoma, adenocarcinoma, breast cancer, sarcoma, and rectal cancer.

"Dr. Riordan has established cancer treatment centers using dendritic cell therapy over a decade ago, yet only this year did the FDA approve this approach," stated Thomas Ichim, CEO of Medistem Inc. "The groundbreaking findings that were granted the current patent attest to the successful integration of basic research and clinical practice that has been pioneered by the founder of Medistem Panama."

Medistem Panama is a biotechnology company located in Panama City, Panama which possesses stem cell isolation, manipulation, expansion, and storage capabilities. As a licensee of the American company, Medistem Inc., it is involved in basic research and applications of cord blood, placental matrix, bone marrow, and adipose derived stem cells. Medistem Panama routinely collaborates with scientists at leading North American Universities including University of California San Diego and University of Western Ontario.

"I am thankful to the clinical and basic research teams that have believed in and supported our dream of using the body's own cells to heal itself," stated Dr. Riordan. "Our current work at Medistem Panama with adult stem cells is a continuation of our dendritic cell work; the only difference is that instead of using the body's cells to fight cancer we are using the body's cells to fight degenerative diseases."

Source:
Medistem Inc.

• Additional
• References
• Citations